Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists (Q37949391)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

25 August 2017

Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists (English)

1 reference

Europe PubMed Central

25 August 2017

Gram-negative bacteria

0 references

0 references

author name string

Natalie Boyd

1

1 reference

Europe PubMed Central

25 August 2017

Michael D Nailor

2

1 reference

Europe PubMed Central

25 August 2017

language of work or name

0 references

publication date

1 November 2011

1 reference

Europe PubMed Central

25 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

25 August 2017

31

1 reference

Europe PubMed Central

25 August 2017

11

1 reference

Europe PubMed Central

25 August 2017

1073-1084

1 reference

Europe PubMed Central

25 August 2017

Ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Methods of testing combined antibiotic bactericidal action and the significance of the results

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Technique for determining the bactericidal effect of drug combinations

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Combination therapy as a tool to prevent emergence of bacterial resistance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro pharmacodynamic models to determine the effect of antibacterial drugs

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Historical review of in-vitro models

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Efficacy of monotherapy in the treatment of Pseudomonas ventilator-associated pneumonia in patients with trauma

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Is monotherapy for febrile neutropenia still a viable alternative?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: utility of a combination antibiogram

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Polymyxins revisited

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Fosfomycin: use beyond urinary tract and gastrointestinal infections

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Tigecycline: a novel broad-spectrum antimicrobial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy*

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.11.1073

21 January 2018

Identifiers

10.1592/PHCO.31.11.1073

1 reference

Europe PubMed Central

25 August 2017

1 reference

Europe PubMed Central

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37949391&oldid=2088618805"